RE:Multiple Myeloma In General and NCT03605719 SpecificallyThought I would look a little deeper.
News Release: BMS - Dec. 6. 2023. Tokyo
The essence is that Abecma (BMS) becomes First CAR T approved for use in earlier lines of therapy for RRMM patients in Japan.
BMS is one of the leaders in MM with a broad reach. They have been very quiet about the trial with ONC. Opdivo (BMS) got added to a pela combo that already had legs.
Add to that the surprise Phase 1b/2 ONC/Merck AMBUSH Trial with Keytruda and we have another player.
Another reason why I am holding strong is that I would not be surprised by a bid from either of those players, especially BMS.
Just trying to put the puzzle pieces together. Nothing solid yet.
PS. I do hope Japan is not in AN's territory. Anyone?